J&J scores another PhIII win for Erleada as it continues to build a blockbuster franchise
Just under a year since J&J won approval from the FDA to start marketing Erleada (apalutamide) for non-metastatic prostate cancer, the pharma giant has now nailed down the late-stage data it needs to prove that it works in metastatic patients as well.
The pharma giant said Wednesday morning that the monitoring committee on the TITAN study called it, flagging the study for its success on both the co-primaries: radiographic progression-free survival as well as overall survival. The actual data will be posted later this year with as much fanfare as the company will be able to muster.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
